| Prev Close | 85.91 |
| Day Low/High | 85.46 / 86.86 |
| 52 Wk Low/High | 62.55 / 101.28 |
AbbVie, Inc. (ABBV)
86.23
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1764.83B |
| Market Cap | 151.62B |
| P/E Ratio | 74.06 |
| Div & Yield | N.A. (N.A) |
Biowreck (Part Deux)
The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.
Biotechs, Autos Look Good in This Selloff
Put cash to work in large-caps that have become cheap in the current market.
Why I'm Adding to My Biotech Positions
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
My Take on Stock Buybacks
One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...
AbbVie Looks Like It's Bottoming Out
Charts show the drug firm has a good entry point approaching.
Anchor Your Portfolio With a Sturdy Front 5
Just as the offensive line is vital to a team's success, so are consistent performers in a portfolio.
AbbVie Has More Downside to Go
The stock has shown awful relative strength.
Another Rally Fades Into the Sunset
China, and Fed rate hike uncertainty, continue to drive volatility.
Let's Go Bottom-Fishing!
The next couple of sessions offer an opportunity to nibble at four names with lower entry points.
Be Ready If This Is Just a One-Day Rally
Have your shopping list of stocks handy in case markets tank again.
Keep Calm and Shop for Bargains
It could be time to deploy some of your dry powder.
Shire Proposes $30B Deal to Buy Disease Specialist Baxalta
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Avoid Gilead Shares for Now
Competition and lower earnings cloud its future.
What to Watch Friday: American Airlines Earnings, New Home Sales
For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).
How to Navigate This Week's Earnings Minefield
Don't make a learning week a gambling week.
What to Watch in the Week Ahead: Apple Earnings, Housing Data
For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.
Looking for the Next Receptos Is Plain Stupid Right Now
These stocks will be up so high today, that many fans will say "no thanks."
The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding
This market is almost entirely special situation.
3 Dividend Hikes This Week You Should Know About
Duke Energy's recent increase puts its payout at the high end of the industry range.
'GILDed Age' Is Over for Gilead Shares
The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.
Biotech Moves Are Anything But Crazy
New companies are coming up with major drugs.
AbbVie Is Knocking on the Door Again
The ABBV chart looks constructive, with solid volume and bullish indicators.
Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.
Deluge of Deals Isn't About to Dry Up
Acquisitions cut into overabundance of companies.
